Earnings
Personalis Clinical Test Volume Triples To 13,157 As Quarterly Loss Widens To $33.8 Million
Revenue rose to $25.6 million from $14.5 million, but selling costs doubled and the pending Tempus AI deal ends guidance and earnings calls.
PSNL
Personalis (PSNL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Merck Is 22% Of Personalis Revenue — And A Related Party Voting For The Tempus Deal
Personalis's largest customer owns more than 10% of its stock, and Tempus fees inside selling costs have jumped to $4.8 million.
Deals
Personalis Tells Holders To Back Tempus Deal Worth $16.25 A Share In Stock, Citing 28% And 64% Premiums
The board unanimously backs the sale and warns that going alone means dilutive financing; holders vote November 30.
Deals
Personalis Holders Vote November 30 On Tempus Deal, Which Carries A $48.42 Floor And A $46.00 Walk-Away
The definitive proxy sets a virtual meeting, a fixed exchange ratio below $48.42 and a termination right for Personalis below $46.00.
Deals
Personalis Tells Employees It Does Not Anticipate Layoffs In Pending Tempus Deal
An employee FAQ says the Fremont site stays open, the stock plan ends and 401(k) contributions pause if closing comes in 2026.
Deals
Personalis Says Antitrust Waiting Period For Tempus AI Merger Expired October 2
A Personalis stockholder vote, on a date not yet set, is now the main step left before the Tempus AI deal can close.